NVRO - Earnings announcements

REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.

Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance REDWOOD CITY, Calif., Nov. 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results, reaffirmed its full-year 2024 revenue guidance and raised its full-year 2024 adjusted EBITDA guidance. "Our worldwide revenue and adjusted EBITDA came in better than we anticipated in the third quarter of 2024. In addition, our cash position reflects the benefits from our restructurings earlier this year as well as our focus on working capital ma

REDWOOD CITY, Calif., Oct. 10, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the third quarter of 2024 after the market closes on Monday, November 11, 2024. The company will also host a conference call beginning at 1:30 p.m. PST (4:30 p.m. EST) to discuss its financial results. The live webcast and replay of the conference call will be available in the Investor Relations section of the company's website at Events & Presentations. The webcast can be accessed 10 minutes prior to the conference call start time. For th

Initiates Process Aimed at Accelerating Growth, Diversifying Product Portfolio and Maximizing Stockholder Value Revises Full-Year 2024 Revenue Guidance to a Range of $400 million to $405 million and Adjusted EBITDA Guidance to a Range of $(20) Million to $(18) Million Provides Third-Quarter 2024 Guidance REDWOOD CITY, Calif., Aug. 6, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its second-quarter 2024 financial results, revised its full-year 2024 guidance, and issued third-quarter 2024 guidance. The company also announced that it is initiating a process

REDWOOD CITY, Calif., July 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the second quarter of 2024 after the market closes on Tuesday, August 6, 2024. The company will also host a conference call beginning at 1:30 p.m. PDT (4:30 p.m. EDT) to discuss its financial results. The live webcast and replay of the conference call will be available in the Investor Relations section of the company's website at Events & Presentations. The webcast can be accessed 10 minutes prior to the conference call start time. For thos

Announces Additional Restructuring Steps to Advance Strategy and Accelerate Profitability Raises Adjusted EBITDA Guidance and Reaffirms Revenue Guidance for Full-Year 2024 Promotes Christofer Christoforou to Chief Operating Officer REDWOOD CITY, Calif., May 7, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its first quarter 2024 financial results. The company also announced additional restructuring steps to advance its strategy and accelerate profitability, raised its adjusted EBITDA guidance and reaffirmed its revenue guidance for the full-year 2024, and

REDWOOD CITY, Calif., April 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the first quarter of 2024 after the market closes on Tuesday, May 7, 2024. The company will also host a conference call beginning at 1:30 p.m. PDT (4:30 p.m. EDT) to discuss its financial results. The live webcast and replay of the conference call will be available in the Investor Relations section of the company's website at Events & Presentations. The webcast can be accessed 10 minutes prior to the conference call start time. For those

Provides Full-Year and First-Quarter 2024 Guidance REDWOOD CITY, Calif., Feb. 21, 2024 /PRNewswire/ --Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2023 financial results. The company also provided first-quarter and full-year 2024 financial guidance. "Our fourth quarter performance reflects continued execution of our three-pillar strategy initiated in the second quarter of 2023," said Kevin Thornal, Nevro's CEO and president. "The actions we have taken, including our commercial realignment, strengthening our executive team with talented and e

REDWOOD CITY, Calif., Jan. 29, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will release its financial results for the fourth quarter and full year ended December 31, 2023 after the market closes on Wednesday, February 21, 2024. The company will also host a conference call on February 21, 2024 to discuss its financial results. The call will begin at 1:30 pm PT / 4:30 pm ET. Investors interested in listening to the call may do so by dialing (888) 330-2443 in the U.S. or +1 (240) 789-2728 internationally, using conference ID: 3583097. A

Company to Host Conference Call on Wednesday, November 1, 2023 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif., Oct. 4, 2023 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will report its financial results for the third quarter ended September 30, 2023 after the market closes on November 1, 2023. Management will host a conference call on November 1, 2023 to discuss third quarter 2023 financial results. The call will begin at 1:30 pm PT/ 4:30 pm ET.  Investors interested in listening to the call may do so by dialing (888) 330-2443 in the U.S.

Company Takes Proactive Steps to Improve Commercial Execution and Maximize Growth Opportunities REDWOOD CITY, Calif., Aug. 1, 2023 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its second quarter 2023 financial results. The company also provided third quarter guidance and updated its full-year 2023 guidance. Recent Business Highlights and Guidance Second Quarter 2023 Worldwide Revenue of $108.8 Million Grew 4% As Reported and Constant Currency Compared to Second Quarter 2022Painful Diabetic Neuropathy (PDN) Indication Sales of Approximately $19.0 Million Grew

Company to Host Conference Call on Tuesday, August 1, 2023 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif., June 27, 2023 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will report its financial results for the second quarter ended June 30, 2023 after the market closes on August 1, 2023. Management will host a conference call on August 1, 2023 to discuss second quarter 2023 financial results. The call will begin at 1:30 pm PT/ 4:30 pm ET.  Investors interested in listening to the call may do so by dialing (888) 330-2443 in the U.S. or +1 (240

Organizational Change Designed to Drive Strong Growth and Advance Global Commercial Focus Company Updates Second Quarter 2023 Revenue Guidance REDWOOD CITY, Calif., June 5, 2023 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Greg Siller has been appointed Senior Vice President and Chief Commercial Officer of Nevro, effective June 19, 2023.  Mr. Siller replaces Niamh Pellegrini, who will be leaving the organization effective June 9.  The company also announced that in conjunction with this appointment, it is updating its revenue guidance for the second q

REDWOOD CITY, Calif., April 26, 2023 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its first quarter 2023 financial results.  The company also provided second quarter guidance and reiterated its full-year 2023 guidance. Recent Business Highlights and Guidance First Quarter 2023 Worldwide Revenue of $96.3 Million Grew 10% As Reported and 11% Constant Currency Compared to First Quarter 2022Painful Diabetic Neuropathy (PDN) Indication Sales of Approximately $15.6 Million Grew 160% Compared to First Quarter 2022First Quarter 2023 U.S. Trial Procedures Increased 9

D. Keith Grossman to be Appointed as Executive Chairman Company Announces Preliminary, Unaudited Worldwide Revenue for First Quarter of 2023 of $96.3 Million and Reaffirms Full-Year 2023 Revenue and Non-GAAP Adjusted EBITDA Guidance REDWOOD CITY, Calif., April 19, 2023 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Kevin Thornal has been appointed Chief Executive Officer and President of Nevro, effective April 24, 2023, and will also be appointed to the Board of Directors.  Mr. Thornal succeeds D. Keith Grossman, who is retiring as Chief Executive Offic

Company to Host Conference Call on Wednesday, April 26, 2023 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif., March 29, 2023 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will report its financial results for the first quarter ended March 31, 2023 after the market closes on April 26, 2023. Management will host a conference call on April 26, 2023 to discuss first quarter 2023 financial results. The call will begin at 1:30 pm PT/ 4:30 pm ET. Investors interested in listening to the call may do so by dialing (888) 330-2443 in the U.S. or +1 (24

REDWOOD CITY, Calif., Feb. 16, 2023 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced its fourth quarter and full-year 2022 financial results.  The company also provided first quarter and complete full-year 2023 guidance. Recent Business Highlights and GuidanceFourth Quarter 2022 Worldwide Revenue of $113.8 Million Grew 11% As Reported and 12% Constant Currency Compared to Fourth Quarter 2021Painful Diabetic Neuropathy (PDN) Indication Sales of Approximately $17.3 Million Grew 329% Compared to Fourth Quarter 2021, Bringing First Full Year of PDN Indication Sales

Company to Host Conference Call on Thursday, February 16, 2023 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif., Jan. 19, 2023 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will report its financial results for the fourth quarter and full year ended December 31, 2022 after the market closes on February 16, 2023. Management will host a conference call on February 16, 2023 to discuss fourth quarter and full-year 2022 financial results. The call will begin at 1:30 pm PT/ 4:30 pm ET.  Investors interested in listening to the call may do so by dia

Company Announces 2023 Retirement Plans of D. Keith Grossman from Positions of CEO and President; Will Remain as Chairman of the Board Company to Present Today at J.P. Morgan Healthcare Conference at 3:45 pm Pacific Time REDWOOD CITY, Calif., Jan. 9, 2023 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced its preliminary, unaudited fourth quarter and full-year 2022 revenue results.  The company also provided full-year 2023 revenue guidance and announced its Chief Executive Officer and President, D. Keith Grossman, has informed the Board of his intention to reti

REDWOOD CITY, Calif., Nov. 2, 2022 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for the third quarter ended September 30, 2022, narrowed its full-year 2022 guidance and raised its full-year revenue contribution from painful diabetic neuropathy (PDN). Recent Business Highlights and GuidanceThird Quarter 2022 Worldwide Revenue of $100.5 Million; Representing 8% As Reported and 10% Constant Currency Growth Compared to Third Quarter 2021PDN Represented Approximately $13.4 Million in Revenue in Third Quarter 2022 Compared to $2.0 Million in Third Quarter 2021;Third Quarter 2022 U.

Company to Host Conference Call on Wednesday, November 2, 2022 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif., Oct. 5, 2022 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will report its financial results for the third quarter ended September 30, 2022 after the market closes on November 2, 2022. Management will host a conference call on November 2, 2022 to discuss third quarter 2022 financial results. The call will begin at 1:30 pm PT/ 4:30 pm ET.  Investors interested in listening to the call may do so by dialing (888) 330-2443 in the U.S.

REDWOOD CITY, Calif., Aug. 3, 2022 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for the second quarter ended June 30, 2022, provided guidance for the third quarter of 2022 and updated its full-year 2022 guidance. Recent Business Highlights and GuidanceSecond Quarter 2022 Worldwide Revenue of $104.2 Million; Representing 2% As Reported and 4% Constant Currency Growth Compared to Prior Year and 11% As Reported and 12% Constant Currency Growth Over Second Quarter of 2019Painful Diabetic Neuropathy (PDN) Represented Approximately $11.0 Million in Revenue in Second Quarter 2022Sec

Company to Host Conference Call on Wednesday, August 3, 2022 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif., July 6, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will report its financial results for the second quarter ended June 30, 2022 after the market closes on August 3, 2022. Management will host a conference call on August 3, 2022 to discuss second quarter 2022 financial results. The call will begin at 1:30 pm PT/ 4:30 pm ET.  Investors interested in listening to the call may do so by dialing (888) 330-2443 in the U.S. or +1 (2

REDWOOD CITY, Calif., May 4, 2022 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for the first quarter ended March 31, 2022, provided guidance for the second quarter of 2022 and reiterated its full-year 2022 revenue guidance. Recent Business Highlights and Guidance First Quarter 2022 Worldwide Revenue of $87.8 Million; Decrease of 1% Compared to Prior Year and Increase of 7% over First Quarter of 2019First Quarter 2022 U.S. Trial Procedures Increased 10% Compared to Prior Year and Increased 13% Compared to First Quarter of 2019, while U.S. PDN trial procedures grew to 11% of to

Company to Host Conference Call on Wednesday, May 4, 2022 at 1:30 pm PT / 4:30 pm ET REDWOOD CITY, Calif., April 6, 2022 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will report its financial results for the first quarter ended March 31, 2022 after the market closes on May 4, 2022. Management will host a conference call on May 4, 2022 to discuss first quarter 2022 financial results. The call will begin at 1:30 pm PT/ 4:30 pm ET.  Investors interested in listening to the call may do so by dialing (888) 330-2443 in the U.S. or +1 (240) 789-27

REDWOOD CITY, Calif., Feb. 23, 2022 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for the fourth quarter and full-year ended December 31, 2021 and provided guidance for the first quarter and full-year of 2022. Recent Business Highlights and Guidance Fourth Quarter 2021 Worldwide Revenue of $102.8 Million; Decrease of 6% Compared to Prior Year and Decrease of 10% Compared to 2019 Fourth Quarter 2021 Worldwide Revenue Includes Approximately $4.0 Million of Painful Diabetic Neuropathy (PDN) Revenue Fourth Quarter 2021 Net Loss from Operations of $26.2 Million; Fourth Quarter 2021

REDWOOD CITY, Calif., Jan. 24, 2022 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will report its financial results for the fourth quarter and full-year ended December 31, 2021 after the market closes on February 23, 2022. Management will host a conference call on February 23, 2022 to discuss fourth quarter and full-year 2021 financial results. The call will begin at 1:30 pm PT/ 4:30 pm ET.  Investors interested in listening to the call may do so by dialing (888) 330-2443 in the U.S. or +1 (240) 789-2728 internationally, using Conference

REDWOOD CITY, Calif., Jan. 10, 2022 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced its preliminary, unaudited fourth quarter and full-year 2021 revenue results and expects to exceed the high end of its previously provided fourth quarter 2021 non-GAAP adjusted EBITDA guidance.     Fourth Quarter 2021 Preliminary, unaudited fourth quarter 2021 worldwide revenue is expected to be approximately $102.5 million, compared to $109.7 million in the fourth quarter in the prior year period and $114.4 million in the fourth quarter of 2019. Worldwide revenue for the fourt

REDWOOD CITY, Calif., Nov. 8, 2021 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported its financial results for the third quarter ended September 30, 2021 and provided fourth quarter of 2021 guidance. Third Quarter Updates, Recent Highlights and Guidance Late July FDA Approval of 10 kHz High Frequency Spinal Cord Stimulation Therapy for Treatment of Chronic Pain Associated with Painful Diabetic Neuropathy (PDN) Third Quarter 2021 Worldwide Revenue of $93.2 Million; Decrease of 14% Compared to Prior Year and Decrease of 7% Compared to 2019 Third Quarter 2021 Worldwide

REDWOOD CITY, Calif., Oct. 11, 2021 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company will report its financial results for the third quarter ended September 30, 2021 after the market closes on November 8, 2021. Management will host a conference call on November 8, 2021 to discuss third quarter 2021 financial results. The call will begin at 1:30 pm PT/ 4:30 pm ET.  Investors interested in listening to the call may do so by dialing (866) 324-3683 in the U.S. or +1 (509) 844-0959 internationally, using Conference ID: 8987949. A live webcast of this e

REDWOOD CITY, Calif., Aug. 4, 2021 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported its financial results for the second quarter ended June 30, 2021 and provided third quarter of 2021 guidance. Second Quarter Updates, Recent Highlights and Guidance FDA Approval of 10 kHz High Frequency Spinal Cord Stimulation Therapy for Treatment of Chronic Pain Associated with Painful Diabetic Neuropathy (PDN) Second Quarter 2021 Worldwide Revenue of $102.3 Million; Increase of 81% Compared to Prior Year and Increase of 9% Compared to 2019 Second Quarter 2021 Net Loss from Operat